Companies / Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
Nasdaq: PTGXCIK 1377121NEWARK, CA
Insider flow · last 90 daysNet sells $2.93M
Financials
Ownership
64.7M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 1.18% | 763,611 |
| 10%+ / strategic | 23.98% | 15,518,262 |
| Institutions | 97.98% | 63,401,852 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 8
View all →| Insider | % of shares | Shares |
|---|---|---|
Patel Dinesh V Ph DCEOPresident and CEO · Director | 0.81% | 523,478 |
Molina Arturo MdChief Medical Officer | 0.13% | 84,115 |
Selick Harold EDirector | 0.09% | 60,845 |
Ali AsifChief Financial Officer | 0.09% | 59,003 |
Giraudo BryanDirector | 0.02% | 12,695 |
O'Dowd Sarah ADirector | 0.01% | 7,825 |
Waddill William D.Director | 0.01% | 7,825 |
Williams Lewis TDirector | 0.01% | 7,825 |
Institutional holders 332
View all →| Holder | Value | % of shares |
|---|---|---|
| $1.26B | 15.93% | |
| $536.62M | 9.49% | |
| $472.83M | 8.37% | |
| $441.86M | 7.82% | |
| $407.16M | 5.13% | |
| $304.87M | 4.47% | |
| $276.99M | 4.90% | |
| $241.93M | 4.28% | |
| $213.91M | 3.78% | |
| $175.98M | 2.58% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | Common stock | $411.60M | +6.2M | 6,196,006 9.58% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $72.55M | +592K +6.09% | 10,307,837 15.93% of shares | high |
| Q2 2026 as of | Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 13F manager | Exit | Common stock | $-49.94M | -572K -100.00% | 0 | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | Common stock | $-41.83M | -397K -38.72% | 628,075 0.97% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Add | Common stock | $25.47M | +242K +9.12% | 2,891,527 4.47% of shares | medium |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common stock | $22.82M | +216K +14.90% | 1,669,371 2.58% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $14.93M | +122K +3.81% | 3,321,554 5.13% of shares | medium |
| Q1 2026 as of | Clearbridge Investments, LLC 13F manager | Add | Common stock | $13.91M | +132K +26.94% | 621,820 0.96% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| State Street Corporation | Passive13G | — |
| Vanguard Group Inc | Passive13G/A | — |
| Farallon Capital Partners, L.P. | Passive13G/A | — |
| RTW Investments, LP | Passive13G/A | — |
| Wellington Management Group LLP | Passive13G | — |
| Vanguard Portfolio Management | Passive13G | — |
| Vanguard Capital Management | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| PTGX | — | 74366E102 |